Delayed resolution of lung inflammation in Il-1rn-/- mice reflects elevated IL-17A/granulocyte colony-stimulating factor expression

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 4, 2012, Pages 436-444

  Hudock, Kristin M ^a   Liu, Yuhong ^a,b   Mei, Junjie ^a,b   Marino, Roberta C ^a,b   Hale, Jason E ^a,b   Dai, Ning ^a,b   Worthen, G Scott ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute lung injury; IL 1 receptor antagonist; IL 1 receptor 1; IL 17A

Indexed keywords

CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; LIPOPOLYSACCHARIDE; PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RNA;

AEROSOL; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL COUNT; GAMMA DELTA T LYMPHOCYTE; GENE DELETION; HISTOLOGY; KNOCKOUT MOUSE; LOBAR PNEUMONIA; LUNG INJURY; LUNG LAVAGE; LYMPHOCYTE COUNT; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REACTION TIME;

ACUTE LUNG INJURY; ANALYSIS OF VARIANCE; ANIMALS; BONE MARROW CELLS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES, CXC; GENE EXPRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-17; INTERLEUKIN-1BETA; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PNEUMONIA; RECEPTORS, INTERLEUKIN-1 TYPE I;

ANIMALIA; MUS;

EID: 84867026447     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0104OC     Document Type: Article

References (50)

1. Gabay C, Palmer G. Mutations in the IL1RN locus lead to autoinflammation. Nat Rev Rheumatol 2009;5:480-482.
2. Arnalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, Fernandez-Capitan C, Madero R, Montiel C. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002;127:331-336. (Pubitemid 34233940)
3. Levy H, Murphy A, Zou F, Gerard C, Klanderman B, Schuemann B, Lazarus R, García KC, Celedón JC, Drumm M, et al. IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol 2009;44:580-593.
4. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J, Striz I. Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. Respir Med 2009;103:773-779.
5. Meyer NJ, Sheu CC, Li M, Chen F, Gallop R, Localio AR, Bellamy S, Kaplan S, Lanken P, Fuchs BF, et al. IL1RN polymorphism is associated with lower risk of acute lung injury in two separate at-risk populations [abstract]. Am J Respir Crit Care Med 2010;181:A1023.
6. Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Armstrong I, Mackenzie A, Haslett C. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191-196. (Pubitemid 126449261)
7. Fiocco U, Vezzu M, Cozzi L, Todesco S. IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy. Reumatismo 2004;56:62-73. (Pubitemid 38596238)
8. Fisher CJ Jr, Dhainaut JA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-1843. (Pubitemid 24169697)
9. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-241.
10. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
11. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3:cm1.
12. Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011;134:8-16.
13. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311-321.
14. Brodlie M, Lordan J, Ward C. Can cells other than Th17 lymphocytes be important sources of IL-17 in the lungs? Thorax 2011;66:1096, author reply 1096-1097.
15. Balamayooran G, Batra S, Fessler MB, Happel KI, Jeyaseelan S. Mechanisms of neutrophil accumulation in the lungs against bacteria. Am J Respir Cell Mol Biol 2010;43:5-16.
16. Yang KY, Arcaroli JJ, Abraham E. Early alterations in neutrophil activation are associated with outcome in acute lung injury. Am J Respir Crit Care Med 2003;167:1567-1574. (Pubitemid 37363369)
17. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011;23:1069-1075.
18. Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD, et al. CXCR2 and CXCL5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest 2012;122:974-986.
19. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-527. (Pubitemid 32835046)
20. Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S, et al. IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar Type II cells in vivo and in vitro. J Immunol 2011;186:3197-3205.
21. Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol 2011;61:179-188.
22. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001;25:335-340. (Pubitemid 32918915)
23. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, Enelow RI, Ross TM, Witztum JL, Kolls JK. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol 2009;183:5301-5310.
24. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55. (Pubitemid 28183358)
25. Hudock KM, Liu Y, Worthen GS. Il-1 receptor knockout mice have an increased early inflammatory response to acute LPS inhalation. Am J Respir Crit Care Med 2010;181:A2770 [abstract].
26. Hudock KM, Liu Y, Worthen GS. Interleukin-1 receptor antagonist knockout mice have an increased acute inflammatory response in the lung after LPS. Am J Respir Crit Care Med 2011;183:A1089 [abstract].
27. Jeyaseelan S, Chu HW, Young SK, Worthen GS. Transcriptional profiling of lipopolysaccharide-induced acute lung injury. Infect Immun 2004;72:7247-7256. (Pubitemid 39552396)
28. Nick JA, Young SK, Arndt PG, Lieber JG, Suratt BT, Poch KR, Avdi NJ,Malcolm KC, Taube C, Henson PM, et al. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol 2002;169:5260-5269. (Pubitemid 35217198)
29. Miyamoto M, Prause O, Sjostrand M, Laan M, Lotvall J, Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol 2003;170:4665-4672. (Pubitemid 36519973)
30. Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal 2010;3:cm2.
31. Mei J, Liu Y, Dai N, Favara M, Greene T, Jeyaseelan S, Poncz M, Lee JS, Worthen GS. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010;33:106-117.
32. Johnston CJ, Finkelstein JN, Gelein R, Oberdorster G. Pulmonary cytokine and chemokine mRNA levels after inhalation of lipopolysaccharide in C57BL/6 mice. Toxicol Sci 1998;46:300-307. (Pubitemid 29069614)
33. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and "emergency" hematopoiesis. Cytokine 2008;42:277-288.
34. Kennedy SM, Borch RF. IL-1b mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis. Exp Hematol 1999;27:210-216. (Pubitemid 29131730)
35. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996;93:11008-11013. (Pubitemid 26333108)
36. Maione F, Paschalidis N, Mascolo N, Dufton N, Perretti M, D'Acquisto F. Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol 2009;77:878-887.
37. Rot A. Chemokine patterning by glycosaminoglycans and interceptors. Front Biosci 2010;15:645-660.
38. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007;117:3786-3799. (Pubitemid 350224089)
39. Brass DM, Hollingsworth JW, Fessler MB, Savov JD, Maxwell AB, Whitehead GS, Burch LH, Schwartz DA. The IL-1 Type 1 receptor is required for the development of LPS-induced airways disease. J Allergy Clin Immunol 2007;120:121-127. (Pubitemid 46990496)
40. Frank JA, Pittet J, Wray C, Matthay MA. Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade. Thorax 2008;63:147-153. (Pubitemid 351236482)
41. Moreland JG, Fuhrman RM, Wohlford-Lenane CL, Quinn TJ, Benda E, Pruessner JA, Schwartz DA. TNF-alpha and IL-1 beta are not essential to the inflammatory response in LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 2001;280:L173-L180.
42. Droemann D, Hansen F, Aries SP, Braun J, Zabel P, Dalhoff K, Schaaf B. Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Respiration 2006;73:340-346. (Pubitemid 43725793)
43. Hannen M, Banning U, Bonig H, Kim YM, Shin DI, Lorenz I, Seeger K, Korholz D. Cytokine-mediated regulation of granulocyte colony-stimulating factor production. Scand J Immunol 1999;50:461-468. (Pubitemid 29503450)
44. Schwabe M, Hartert A, Bertz H, Finke J. Treatment with granulocyte colony-stimulating factor increases interleukin-1 receptor antagonist levels during engraftment following allogeneic stem-cell transplantation. Eur J Clin Invest 2004;34:759-765. (Pubitemid 39524301)
45. Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MMC, Jansen J, Wouter ten Cate J, van Deventer S. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997;90:1415-1424. (Pubitemid 27356396)
46. Zhang J, Xiang D, Zhu S, Mao W, Lu H, Wu M, Wang Q, Yu Y, Herbst KD, Han W. Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse. Biomed Pharmacother 2009;63:501-508.
47. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100:5986-5990. (Pubitemid 36576918)
48. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184:252-258.
49. Traves SL, Donnelly LE. Th17 cells in airway diseases. Curr Mol Med 2008;8:416-426.
50. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgård U, Cowen EW, Pham T, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009;360:2426-2437.